Dr Reddy

Adani Infra to acquire 30% stake in PSP projects. Tata Power partners with Bhutan's Druk Green Power Corporation to develop 5,000 MW of clean energy projeects in Bhutan. Watch here for my details

Why should one avoid fresh bets on Dr Reddy’s?

The Revlimid opportunity is transitional and its contribution to profitability is likely to reduce from CY27

Dr Reddy's Laboratories incorporates wholly-owned subsidiary in Jamaica; stock rises 1%

Dr Reddy’s stock has given a return of 18.88 percent over the last six months. The benchmark Nifty50 index has given a return of 14.30 percent over the same duration.

Who makes a better suitor for Cipla and what is in it for shareholders?

Torrent Pharma and Dr Reddy’s are among the bidders. The combined India business can surpass Sun Pharma’s from any of these two deals. Investors in both Dr Reddy’s and Cipla should wait for clarity to emerge

Another great quarter for Dr Reddy’s, but is it sustainable?

EMs are expected to remain the chief driver of top-line growth, driven by chronic therapies and biosimilars

Dr Reddy’s completes phase 1 study of key anti-rheumatic biosimilar drug

The company is now initiating a global study to compare the efficacy, safety and immunogenicity of the proposed medication.

Cash Trade | Dr Reddy's bouncing off channel support

Dr Reddy's is trading in a small channel between 4300 and 4500

Markets extend rally to 3rd day; Sensex climbs over 300 points

The 30-share BSE benchmark advanced 303.38 points or 0.56 per cent to settle at 54,481.84. During the day, it jumped 448.68 points or 0.82 per cent to 54,627.14.

Dr Reddy’s: Acceleration in EM opportunity to help re-rate company

Dr Reddy’s area of focus in the domestic market includes hepatology, diabetic nutrition and its health-tech platform

Dr Reddy’s: Improving exposure to EMs adds to investment case

Situation in Russia presents an opportunity for Indian pharma companies to gain market share in Russia

COVID-19 vaccine | India's Dr. Reddy's in talks with government to bring Russia's Sputnik Light

Dr. Reddy's is also in talks with the Indian government and the private sector to supply the two-dose Sputnik V vaccine, which the company expects to commercially launch in the country in the middle of next month.

Deregulation of vaccine rollout: What it means for pharma players

Dr Reddy’s, Gland Pharma, Strides, Cadila, Aurobindo are some of the names that merit a close watch as operating leverage plays out

Ideas For Profit | What the second covid-19 ‘wave’ means for domestic pharma companies?

With the second Covid ‘Wave’ already surpassing the daily highs recorded in the month of September 2020 of about 95000, the demand for vaccines, critical medical equipment like vaccines, oxygen cylinders and ventilators have increased manifold. Watch the video to know what this evolving situation means for Indian Pharma?

COVID Vaccine: The opportunities for investors - Part I

Vaccine rollout will throw up opportunities not just for the domestic pharmaceutical and healthcare industry but also the logistics value chain, right from vaccine production, delivery, storage and then the actual immunisation

Cadila: a formidable play in Covid times and beyond

Cadila is not only a credible Indian pharma striving for a Covid solution, but on a longer time scale is an interesting watch in the large-cap space witnessing a significant transformation in product portfolio.

Ideas For Profit | Dr Reddy’s: An opportunity for risk takers

Primed by strong bets on complex pharma opportunities

Dr Reddy's to recall 1,752 bottles of heartburn drug in the US

Drug major Dr Reddy's Laboratories is recalling 1,752 bottles of generic heartburn medicine in the US after the American health regulator found quality issues with the product.

Dr Reddy's launches generic lipid-regulating tablets in US

The company's tablets are available in 54 mg dose in bottle count size of 90, and 160 mg dose in bottle count sizes of 90 and 500

Rising stars? 14 stocks reported over 100% surge in PAT

Experts feel there are only a handful of companies that could be considered for investment for the year 2020

Dr Reddy’s plummets 23% as Jefferies red flags ‘repeat’ observations

According to a CNBC-TV18 report, Jefferies, in its research note, has said that the Form 483 issued by US Food and Drug Administration (US FDA) contains four repeat observations out of the total 11 observations.

Dr Reddy’s Labs falls 4% as US FDA issues 11 observations to Bachupally plant

The company on Friday told the exchanges that its Formulations Manufacturing Plant - 3 at Bachupally, Hyderabad had been inspected by the US FDA. It has been issued a Form 483 with 11 observations.

Upbeat CLSA view, procedural observations from US FDA send DRL stock up 3%

The global broking firm also observed that three products, Nuvaring, Suboxone & Copaxone will be major contributors over FY19-20. In fact, the EPS for FY20 could see an upside of 44 percent to Rs 210 if these products are introduced.

Dr Reddy’s tanks 6% on dismal Q1; brokerages turn cautious on stock

Say headwinds in US hit financials, highlight further risks in terms of remediation delays at its plants.

Dr Reddy’s US FDA developments get a thumbs up from brokerages

Cite positive news on the regulatory front, but pain for Duvvada plant may remain, they say.

Dr Reddy's Labs Q4: Analysts see hope in US biz recovery, reduced regulatory concerns

Brokerages largely remain optimistic about the pharma major’s improvement in US business as well as reduced regulatory risks, while some also highlight the seriousness of US FDA’s observations at some of its plants.